Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.


IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

Online
ISSN
1437-4331
See all formats and pricing

 


Select Volume and Issue

Issues

30,00 € / $42.00 / £23.00

Get Access to Full Text

Immunostimulatory CpG Motifs Trigger a T Helper-1 Immune Response to Human Immunodeficiency Virus Type-1 (HIV-1) gp160 Envelope Proteins

Ludwig Deml / Reinhold Schirmbeck / Jörg Reimann / Hans Wolf / Ralf Wagner

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 37, Issue 3, Pages 199–204, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.1999.037, June 2005

Publication History

Published Online:
2005-06-01

Abstract

Bacterial DNA sequences containing unmethylated CpG motifs have recently been proposed to exhibit immunostimulatory effects on B-, T- and NK cells, leading to the induction of humoral and cell-mediated immune responses. In the present study we investigated the immunomodulatory effects of a CpG-containing oligodeoxynucleotide (CpG ODN) to the HIV-1 gp160 envelope (Env) protein in the BALB/c mouse model. Priming and boosting of mice with gp160 adsorbed to aluminium hydroxide (Alum) induced a typical T helper-2 (Th2)-dominated immune response with high titers of gp160-specific immunoglobulin (Ig)G1 isotypes but a weak IgG2a response. Specifically re-stimulated splenocytes from these mice predominantly secreted interleukin (IL)-5 but only minute amounts of interferon-γ (IFN-γ) upon specific re-stimulation. In contrast, a boost immunisation of gp160/Alum primed mice with a gp160/Alum/CpG combination resulted in a seven times higher production of IgG2a antibodies, without affecting the titers of IgG1 isotypes. Furthermore, approximately 10-fold increased levels of IFN-γ, but significantly reduced amounts of IL-5, were secreted from gp160-restimulated splenic cells. A further greater than 30-fold increase in the levels of specific IgG2a responses and a substantially elevated secretion of IFN-γ were observed when the mice received gp160/Alum/CpG combinations for priming and boost injections. Thus, CpG ODNs are useful as an adjuvant to induce a typical Th0/Th1 response to HIV gp160 proteins. However, despite the induction of a more Th1-like immune response, gp160/Alum/CpG combinations were not sufficient to prime an Env-specific cytotoxic T-cell (CTL) response.

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Kanakatte Raviprakash, Dan Ewing, Monika Simmons, Kevin R Porter, Trevor R Jones, Curtis G Hayes, Richard Stout, and Gerald S Murphy
Virology, 2003, Volume 315, Number 2, Page 345
[2]
Yimeng Wang, Chunqiao Shan, Shuangxi Ming, Yan Liu, Yuchun Du, and Guotuo Jiang
Research in Veterinary Science, 2009, Volume 86, Number 3, Page 399
[3]
Søren Kamstrup, Daniela Verthelyi, and Dennis M Klinman
Veterinary Microbiology, 2001, Volume 78, Number 4, Page 353
[4]
Ludwig Deml, Cornelia Speth, Manfred P. Dierich, Hans Wolf, and Ralf Wagner
Molecular Immunology, 2005, Volume 42, Number 2, Page 259
[5]
C.L Cooper, H.L Davis, M.L Morris, S.M Efler, A.M Krieg, Y Li, C Laframboise, M.J Al Adhami, Y Khaliq, I Seguin, and D.W Cameron
Vaccine, 2004, Volume 22, Number 23-24, Page 3136
[7]
Hongming Chen
Journal of Controlled Release, 2000, Volume 67, Number 2-3, Page 117
[8]
Kaley D. Wilson, Susan D. de Jong, and Ying K. Tam
Advanced Drug Delivery Reviews, 2009, Volume 61, Number 3, Page 233
[9]
Ronald B. Moss, Jocelyn Diveley, Fred C. Jensen, Erin Gouveia, Jay Savary, and Dennis J. Carlo
Journal of Interferon & Cytokine Research, 2000, Volume 20, Number 12, Page 1131
[10]
Ryoichi Satoh, Masako Kotake, Tomomi Takano, Kenji Motokawa, Tsuyoshi Gemma, Rie Watanabe, Setsuo Arai, and Tsutomu Hohdatsu
Microbiology and Immunology, 2011, Volume 55, Number 3, Page 184
[11]
[12]
Lei Chen, Miao Xu, Zhi-Yu Wang, Bao-Wen Chen, Wei-Xin Du, Cheng Su, Xiao-Bing Shen, Ai-Hua Zhao, Na Dong, Ya-Jun Wang, and Guo-Zhi Wang
FEMS Immunology & Medical Microbiology, 2010, Volume 59, Number 1, Page 42
[13]
Risini D Weeratna, Cynthia L Brazolot Millan, Michael J McCluskie, and Heather L Davis
FEMS Immunology & Medical Microbiology, 2001, Volume 32, Number 1, Page 65
[14]
Tim H Scott-Taylor and Angus G Dalgleish
Expert Opinion on Investigational Drugs, 2000, Volume 9, Number 3, Page 471
[16]
Y.-J. Guo, D. Wu, K.-Y. Wang, and S.-H. Sun
Scandinavian Journal of Immunology, 2007, Volume 66, Number 6, Page 619
[17]
Anne Krug, Simon Rothenfusser, Veit Hornung, Bernd Jahrsdörfer, Susan Blackwell, Zuhair K. Ballas, Stefan Endres, Arthur M. Krieg, and Gunther Hartmann
European Journal of Immunology, 2001, Volume 31, Number 7, Page 2154
[19]
Risini Weeratna, Lacrimioara Comanita, and Heather L Davis
Immunology and Cell Biology, 2003, Volume 81, Number 1, Page 59

Comments (0)

Please log in or register to comment.